Manufactures weight loss, weight management, and healthy living products. Distributes products in the United States and the Asia-Pacific region. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 29% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 62% of them.
Analysts' average target sits 396% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $167.3M in the vault; even if every debt were paid off, $150.5M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 33 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $18.7M against $385.8M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 4/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 43/100.
On our five-subject report card, MED sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MED’s sales are going backwards, and it closed last year at a loss. The road back runs through both.